On January 10, 2020, the Central Committee of the Communist Party of China and the State Council held the 2019 National Science and Technology Awards Conference in Beijing. This is an annual feast for the scientific and technological community, the highest honor for the Chinese scientific and technological community, and the highest praise for scientific and technological workers from the party and the people. Sun Lingyun and Zhang Huayong from the Department of Rheumatology and Immunology, Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Hu Xiang from Shenzhen Beike Biotechnology Co., Ltd., Wang Dandan from Gulou Hospital, Liu Muyun from Beike Biotechnology, and Xu Wenrong from Jiangsu University. font-stretch: inherit; font-size: inherit; line-height: inherit; font-family: inherit; vertical-align: baseline;”>Key technological innovation and clinical application research on allogeneic mesenchymal stem cells for the treatment of refractory lupus erythematosus” won the second prize of the National Technology Invention Award.
For the first time, the team applied allogeneic MSC to treat refractory SLE. The efficacy was significant, with an effective rate of 60%, no serious adverse reactions, and the 5-year mortality rate was reduced from 45% to 16%. Allogeneic MSC treatment has saved the lives of many severely ill patients and has also opened up new treatment avenues for other refractory autoimmune diseases. The team has conducted a total of 523 research cases of allogeneic MSC treatment of refractory SLE, and has been promoted and applied to 35 units inside and outside the province. Among the team’s research results, the team has obtained 18 authorized invention patents for core technologies, 151 SCI papers, a cumulative impact factor of 657, 4395 citations, more than 30 presentations at the American College of Rheumatology and the European Bone Marrow Transplantation Congress, and 13 invited presentations at international conferences in the past five years. It has held many stem cell academic conferences and national-level continuing education classes, with more than 5,000 participants, cultivating a large number of domestic and foreign talents in the field of stem cell research, and enhancing the international influence of my country’s stem cell clinical translation research.
In recent years, with the continuous advancement of biomedical technology, cell therapy with stem cell regenerative medicine as the core has begun to lead the revolutionary development of future medicine. In the context of cell therapy becoming a new field of global medicine, domestic cell and stem cell clinical research has become a major event related to the “Healthy China” strategy and people’s health. For a long time, the country has introduced a series of government support for the development of the domestic cell industry, and at the same time, it has also put forward deeper needs for basic cell research, clinical research, and scientific and technological research.
The source of scientific and technological innovation means “the source of innovation, inspiring the future.” Among the three major awards of the National Science and Technology Award – Natural Science Award, Technology Invention Award, and Science and Technology Progress Award, the National Technology Invention Award has always been the vane of key scientific and technological discoveries and inventions. As the highest honor in China’s scientific and technological circles, it is the highest praise for the efforts made by Drum Tower Hospital, Beike Biotech and Jiangsu University in the field of stem cells.
Innovation is the inexhaustible driving force for national prosperity. Beike Biotechnology has always regarded innovation as the core and foundation of the company’s development. It insists on leading the high-quality development of my country’s cell industry with R&D and standardization simultaneously, and promotes the initiative and voice of my country’s cell industry in the formulation of international cell industry standards. It truly integrates the destiny of Beike Biotechnology into industrial development and national revitalization. It forges ahead with innovation and passion, and makes important contributions to realizing the grand blueprint of the “Healthy China 2030” strategy and promoting the improvement of people’s health.
Beike Biological Standardization Construction:
In 2016, Beike Biotech took the lead in drafting and compiling the Shenzhen local standard “SZDB/Z 188-2016 Cell Preparation Center Construction and Management Specifications”;
In 2016, Beike Biotech participated in the formulation of the “Self-regulatory Code for Quality Management of Stem Cell Preparation Preparation” and the “Self-Regulatory Code of Quality Management for Preparation of Immune Cell Preparation”;
In 2017, Beike Biotech took the lead in drafting and compiling the Shenzhen local standard “SZDB/Z 266-2017 Comprehensive Cell Bank Setup and Management Specifications”;
In 2018, Beike Biotech participated in the formulation of group standards: “SZTT/SSCT 002-2018 Specification for Human Umbilical Cord-Derived Mesenchymal Stem Cell Preparations for Clinical Research”;
In 2018, Beike Biotech formulated “Q/BKSW 001-2018 Umbilical Cord-Derived Mesenchymal Stem Cells for Scientific Research”;
In 2019, Beike Biotech was awarded the titles of “R&D and Standardization Simultaneous Demonstration Enterprise” and “Standardization Innovation Demonstration Base” recognized by the Shenzhen Municipal Administration for Market Regulation.